KIR3DL1 in acute myeloid leukaemia.
This project centres on KIR3DL1 polymorphism and how it translates to improved outcomes in hematopoietic stem cell transplantation for the treatment of haematological malignancy. Combining functional and clinical data, the aim is to understand KIR in donor selection for HSCT treatment of AML.
Dr Julian Vivian
For further information about this project, contact: